Skip to main content
SpringerLink
Log in

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Two studies have been done to establish recommendations for dosage and dose adjustment in the treatment of deep vein thrombosis (DVT) with low molecular weight heparin (LMWH). In the first, 56 patients were randomized in a double blind study to be treated either with unfractionated heparin (UFH) or LMWH s. c. every 12 h. Initial doses were given according to age and sex, disregarding bodyweight, and the dose was then adjusted when the peak plasma heparin concentration fell outside the desired range of 0.5–0.8 anti-FXa U/ml.

There were fewer dose adjustments in the LMWH group. The correlation between injected dose (U/kg bodyweight) and the heparin concentration was higher in the LMWH group (r=0.59) than in the UFH group (r=0.38). The results suggest that, in order to obtain the desired heparin concentration, the initial dose of LMWH should be about 100 U/kg bodyweight every 12 h.

In the second, open study, this dosage plan was followed in 15 patients. The peak heparin concentration on Day 2 ranged from 0.40 to 0.75 anti-FXa U/ml and adjustment was only required in 3 patients. Day to day variation in peak heparin activity in the individual patient varied little (CV 11–22%), and there was no accumulation.

The results indicate that plasma heparin concentration is more predictable using LMWH than UFH, and they point to definite advantages in the use of LMWH in a bodyweight adjusted dosage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Holmer E, Kurachi K, Söderström G (1981) The molecular-weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor Xia, Factor XIIa and kallikrein by antithrombin. Biochem J 193: 395–400

    Google Scholar 

  2. Anderson LO, Barrowcliffe TW, Holmer E, Johnson EA, Söderström G (1979) Molecular weight dependency of the heparin potentiation of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 15: 531–541

    Google Scholar 

  3. Thunberg L, Lindahl U, Tengblad N, Laurent TC, Jackson CM (1979) On the molecular-weight-dependency of the anticoagulant activity of heparin. Biochem J 181: 241–243

    Google Scholar 

  4. Holmer E, Lindahl U, Backstrom G, Thunberg L, Sandberg H, Söderström G, Andersson L-O (1980) Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 18: 861–869

    Google Scholar 

  5. Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J (1984) A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 35: 613–625

    Google Scholar 

  6. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M (1982) The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59: 1239–1245

    Google Scholar 

  7. Carter CJ, Kelton JG, Hirsh J, Gent M (1981) Relationship between antithrombotic and anticoagulant effect of low molecular weight heparin. Thromb Res 21: 169–174

    Google Scholar 

  8. Levine MN, Hirsh J (1988) An overview of clinical trials of low molecular weight heparin fractions. Acta Chir Scand 154 [Suppl 543]: 73–79

    Google Scholar 

  9. Kehr A, Heilmann JJ, Barbier P (1988) Prevention of postoperative thromboembolism in orthopedic surgery. Therapie 43: 193–198

    Google Scholar 

  10. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G (1986) Prospective double-blind comparison between Fragmin and conventional low-dose heparin: Thromboprophylactic effect and bleeding complications. Haemostasis 16 [Suppl 2]: 11–18

    Google Scholar 

  11. Kakkar VV (1984) Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction. Nouv Rev Fr Hematol 26: 277–282

    Google Scholar 

  12. Planes A, Vochell N (1986) Enoxaparin LMW heparin: Its use in prevention of DVT following total hip replacement. Haemostasis 16: 152–158

    Google Scholar 

  13. ten Cate H, Henny CP, ten Cate JW, Buller H, Mooy M, Surachno S, Wilmink J (1985) Anticoagulant effect of a low molecular weight heparinoid (ORG 10172) in human volunteers and haemodialysis patients. Thromb Res 38: 211–222

    Google Scholar 

  14. Lane DA, Flynn A, Ireland H, Anastassiades E, Curtis JR (1986) On the evaluation of heparin and low molecular weight heparin in haemodialysis of chronic renal failure. Haemostasis 16 [Suppl 2]: 38–47

    Google Scholar 

  15. Schrader J, Kandt M, Zurcher C, Kostering H, Scheler F (1986) Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients. Haemostasis 16 [Suppl 2]: 48–58

    Google Scholar 

  16. Bratt G, Tornbohm E, Granqvist S, Aberg W, Lochner D (1985) A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 54: 813–817

    Google Scholar 

  17. Holm HA, Ly B, Handeland G, Abildgaard U, Arnesen KE, Gottchalk P, Hoegh V (1986) Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 16 [Suppl 2]: 30–37

    Google Scholar 

  18. Lochner D, Bratt G, Tornbohm E, Aberg W, Granqvist S (1986) Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 16 [Suppl 2]: 25–29

    Google Scholar 

  19. Bara L, Samama M (1988) Pharmacokinetics of low molecular weight heparins. Acta Chir Scand [Suppl 543]: 65–72

  20. Bratt G, Toernbohm E, Lochner D, Bergstroem K (1985) A human pharmacological study comparing conventional heparin and low molecular weight heparin fragment. Thromb Haemostasis 53: 208–211

    Google Scholar 

  21. Bergqvist D, Hedner U, Sjoerin E, Holmer E (1983) Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 32: 381–391

    Google Scholar 

  22. Arnesen KE, Handeland G, Abildgaard U (1987) What is the optimal dosage of LMW heparin in the SC treatment of deep venous thrombosis? Thromb Haemost 58: 214

    Google Scholar 

  23. Handeland GF (1986) Simplified chromogenic substrate assay for low molecular weight heparin. Thromb Res 42: 105–108

    Google Scholar 

  24. Teien AN, Lie M (1977) Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified antithrombin III. Thromb Res 10: 399–410

    Google Scholar 

  25. Rabinov K, Paulin S (1972) Roentgen diagnosis of venous thrombosis in the leg. Archs Surg 104: 134–144

    Google Scholar 

  26. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Algazy KM (1977) Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 84: 1018–1029

    Google Scholar 

  27. Holm HA, Abildgaard U, Kalvenes S, Andersen N, Anker E, Arnesen KE, Blinkom D, Drivenes A (1984) The antithrombotic effect of heparin in deep venous thrombosis: Relation to four heparin assays. Acta Med Scand 216: 287–293

    Google Scholar 

  28. Holm HA, Finnanger B, Hartmann A, L. rum F, Lohren O, Ruud TE, Stray N, Wolland T (1984) Heparin treatment of dep venous thrombosis in 280 patients: Symptoms related to dosage. Acta Med Scand 215: 47–53

    Google Scholar 

  29. Bara G, Billaud E, Gramond G, Kher A, Samama M (1985) Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 39: 631–636

    Google Scholar 

  30. Morabia A (1986) Heparin doses and major bleedings. The Lancet I: 1278–1279

    Google Scholar 

  31. Holm HA, Abildgaard U, Kalvenes S (1985) Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost 53: 278–281

    Google Scholar 

  32. Abildgaard U (1989) Monitoring heparin treatment. In: Lane DA, Lindal U (ed) Heparin, chemical and biological properties, clinical applications. Arnold, London, pp 495–515

    Google Scholar 

  33. Albada J, Nieuwenhuis HK, Sixma JJ (1989) Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin). Circulation 80: 935–940

    Google Scholar 

  34. Huet Y, Gouault-Heilmann M (1986) Low molecular weight heparin fraction PK 10169: A new therapeutic means for anticoagulant therapy? Haemostasis 16: 165–172

    Google Scholar 

  35. Hull RD, Raskob G, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D (1986) Continous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315: 1109–1114

    Google Scholar 

  36. Talstad I (1985) Heparin therapy adjusted by bodyweight. Am J Clin Pathol 83: 378–385

    Google Scholar 

  37. Lochner D, Bratt G, Tornebohm E, Åberg W (1986) Pharmacokinetics of intravenous and subcutaneously administered Fragmin in Healthy volunteers. Haemostasis 16 [Suppl 2]: 8–10

    Google Scholar 

  38. Dawes J, Bara L, Billaud E, Samama M (1986) Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 16: 116–122

    Google Scholar 

  39. Rowland M, Tozer TN (1980) Clinical Pharmacokinetics, Concepts and Applications. Lea and Febiger, Philadelphia, p 20

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department, Aker Hospital, Oslo

    G. F. Handeland, U. Abildgaard & H. A. Holm

  2. Medical Department, Akershus Central Hospital, 1474 Nordbyhagen, Norway

    K. E. Arnesen

Authors
  1. G. F. Handeland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Abildgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. A. Holm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. E. Arnesen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Handeland, G.F., Abildgaard, U., Holm, H.A. et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39, 107–112 (1990). https://doi.org/10.1007/BF00280041

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00280041

Key words

Search

Navigation